🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed/Refractory Multiple Myeloma (RRMM)

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT05519085Phase 3266 sites📍 Los Alamitos📍 San Diego📍 West Hollywood Celgene · Tests: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) NCT07227311Phase 259 sites📍 Los Alamitos📍 Torrance📍 Whittier GlaxoSmithKline · Tests: Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" NCT07382739Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Elranatamab A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma NCT07681596Phase 1, Phase 212 sites📍 Duarte📍 Denver📍 Tampa AstraZeneca · Tests: AZD4045, Daratumumab, Aldesleukin Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma NCT07497165n/a1 site📍 Taiyuan Shanxi Bethune Hospital A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma NCT07579234Phase 31 site📍 Tianjing Shandong New Time Pharmaceutical Co., LTD · Tests: F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma NCT07715630Phase 11 site📍 Kunming Chongqing Precision Biotech Co., Ltd · Tests: Invivo CAR-T A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments NCT05137054Phase 142 sites📍 La Jolla📍 Atlanta📍 Indianapolis Regeneron Pharmaceuticals · Tests: Linvoseltamab, Daratumumab, Carfilzomib, Lenalidomide, Bortezomib Isatuximab in Combination With Novel Agents in RRMM - Master Protocol NCT04643002Phase 1, Phase 225 sites📍 Atlanta📍 Chicago📍 Ann Arbor Sanofi · Tests: Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects NCT07280013Phase 120 sites📍 Gilbert📍 Sacramento📍 Santa Monica C4 Therapeutics, Inc. · Tests: Cemsidomide, Elranatamab A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma NCT05651932Phase 129 sites📍 San Francisco📍 Jacksonville📍 Miami K36 Therapeutics, Inc. · Tests: Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYP… A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients NCT03110822Phase 113 sites📍 Alhambra📍 Bakersfield📍 Encinitas Oncotherapeutics · Tests: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma NCT07032714Phase 13 sites📍 Boston📍 Boston📍 Boston Massachusetts General Hospital · Tests: Talquetamab, Mezigdomide, Dexamethasone A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) NCT07558915Phase 11 site📍 Parkville Genentech, Inc. · Tests: RO7851624 Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003568Phase 11 site📍 Shanghai Beijing GoBroad Hospital · Tests: Dual-targeting BCMA-GPRC5D CAR-T cell infusion Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies NCT07051850n/a1 site📍 Seocho Sung-Soo Park · Tests: Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody, Proteasome Inhibitor, IMiD treatment HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM NCT06822972Phase 21 site📍 Durham Duke University · Tests: Selinexor 40 mg A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma NCT07637578Phase 26 sites📍 Denver📍 Denver📍 Columbia SCRI Development Innovations, LLC · Tests: Elranatamab, Tocilizumab Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) NCT07609940Phase 45 sites📍 Los Angeles📍 St. Petersburg📍 Baton Rouge Regeneron Pharmaceuticals · Tests: Linvoseltamab, Tocilizumab Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM NCT06518551Phase 1, Phase 23 sites📍 Boston📍 Boston📍 Boston Omar Nadeem, MD · Tests: Elotuzumab, Iberdomide, Dexamethasone A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) NCT07222761Phase 344 sites📍 Atlanta📍 New York📍 Columbus Regeneron Pharmaceuticals · Tests: Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide GR1803 Injection in Patients With RRMM NCT06952075Phase 21 site📍 Tianjin Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Tests: GR1803 ELISA in Relapsed/Refractory MM NCT06832865Phase 23 sites📍 Boston📍 Boston📍 Boston Massachusetts General Hospital · Tests: elranatamab, Isatuximab SC, Isatuximab SC-OBDS Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma NCT06961669NA1 site📍 Hefei Anhui Provincial Hospital · Tests: Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma NCT07455851Phase 1, Phase 28 sites📍 Randwick📍 Wollongong📍 Adelaide Regeneron Pharmaceuticals · Tests: Linvoseltamab, REGN17372+Linvoseltamab Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma NCT06297226Phase 252 sites📍 Birmingham📍 Gilbert📍 Little Rock Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Tests: Arlocabtagene Autoleucel A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia NCT05759793Phase 11 site📍 Shanghai Nanjing IASO Biotechnology Co., Ltd. · Tests: CAR-GPRC5D A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma NCT05730036Phase 3159 sites📍 Los Angeles📍 Gainesville📍 Lexington Regeneron Pharmaceuticals · Tests: Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma NCT06115135Phase 22 sites📍 West Hollywood📍 Omaha Oncotherapeutics · Tests: Venetoclax Delayed Toxicities Post-CAR-T NCT07665307n/a3 sites📍 San Francisco📍 New York📍 New York Icahn School of Medicine at Mount Sinai
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy